Delayed melatonin administration promotes neuronal survival, neurogenesis and motor recovery, and attenuates hyperactivity and anxiety after mild focal cerebral ischemia in mice
- 12 August 2008
- journal article
- Published by Wiley in Journal of Pineal Research
- Vol. 45 (2), 142-148
- https://doi.org/10.1111/j.1600-079x.2008.00568.x
Abstract
Melatonin is a potent antioxidant with neuroprotective activity in animal models of ischemic stroke, which based on its lack of serious toxicity has raised hopes that it might be used for human stroke treatment in the future. This study investigated how subacute delivery of melatonin, starting at 24 hr after stroke onset, and continuing for 29 days (4 mg/kg/day; via drinking water), influences neuronal survival, endogenous neurogenesis, motor recovery and locomotor activity in C57Bl6/j mice submitted to 30‐min middle cerebral artery occlusion. Histologic studies showed that melatonin improved neuronal survival and enhanced neurogenesis, even when applied 1 day after stroke. Cell survival was associated with a long‐lasting improvement of motor and coordination deficits, evaluated by the grip strength and RotaRod tests, as well as with attenuation of hyperactivity and anxiety of the animals as revealed in open field tests. The robust functional neurologic improvements encourage proof‐of‐concept studies with melatonin in human stroke patients.Keywords
This publication has 46 references indexed in Scilit:
- Neuroprotection in the SAINT-II aftermathAnnals of Neurology, 2007
- Tissue plasminogen activator-induced reperfusion injury after stroke revisited.Circulation, 2007
- Life After CeroviveStroke, 2007
- Future of neuroprotection for acute stroke: In the aftermath of the SAINT trialsAnnals of Neurology, 2007
- Implications of ATP-binding cassette transporters for brain pharmacotherapiesTrends in Pharmacological Sciences, 2007
- Preclinical evaluation of pharmacokinetics and safety of melatonin in propylene glycol for intravenous administrationJournal of Pineal Research, 2006
- 1,026 Experimental treatments in acute strokeAnnals of Neurology, 2006
- Multitargeted Effects of Statin-Enhanced Thrombolytic Therapy for Stroke With Recombinant Human Tissue-Type Plasminogen Activator in the RatCirculation, 2005
- Aggravation of Focal Cerebral Ischemia by Tissue Plasminogen Activator Is Reversed by 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor but Does Not Depend on Endothelial NO SynthaseStroke, 2005
- Recommendations for Standards Regarding Preclinical Neuroprotective and Restorative Drug DevelopmentStroke, 1999